In the scenario where LGALS9C represents a particular enzyme or receptor, LGALS9C inhibitors would comprise a class of molecules tailored to bind to and impede the activity of this target. These inhibitors would be characterized by their structural affinity for LGALS9C, engaging with it at specific sites crucial for its function. The chemical structure of these inhibitors would be designed to correspond with the binding regions of the LGALS9C, whether these are enzymatic active sites, binding pockets, or allosteric sites. The inhibitors could work by mimicking the natural substrate of the enzyme or receptor, thereby preventing the actual substrate from binding, or by inducing conformational changes in LGALS9C that would result in the loss of its activity. The development of such inhibitors would likely involve extensive research into the structure and function of LGALS9C, including its three-dimensional configuration, the dynamics of its active site, and the nature of its interaction with ligands or substrates.
The process of designing and refining LGALS9C inhibitors would be highly iterative, involving synthesis and functional assays to assess the efficacy of binding and inhibition. Medicinal chemists might employ computer-aided drug design (CADD) techniques to model the interactions between potential inhibitors and LGALS9C, allowing for the virtual screening of compound libraries and the prediction of binding affinities. This process would be supplemented by empirical testing, including binding studies and activity assays, to validate computational predictions. Structural modifications would be made to optimize interactions, such as improving hydrophobic contacts or enhancing hydrogen bonding with the target. The aim would be to develop molecules that exhibit a high degree of specificity for LGALS9C, ensuring that they effectively inhibit the target without interacting with other proteins or enzymes. The physicochemical properties of these inhibitors, like solubility, permeability, and metabolic stability, would also be crucial factors in the design process, directed towards maximizing the potential for effective interaction with LGALS9C.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound can incorporate into DNA and RNA, leading to hypomethylation of DNA, which can alter gene expression patterns, potentially reducing LGALS9C expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Similar to 5-Azacytidine, Decitabine is a DNA methyltransferase inhibitor that leads to DNA hypomethylation and could alter gene expression. | ||||||
Hydralazine-15N4 Hydrochloride | 304-20-1 (unlabeled) | sc-490605 | 1 mg | $480.00 | ||
Hydralazine is known to demethylate DNA by inhibiting DNA methyltransferase, which might result in altered expression of LGALS9C. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108 is a non-nucleoside DNA methyltransferase inhibitor, which could prevent methylation of the LGALS9C gene, potentially reducing its expression. | ||||||
Zebularine | 3690-10-6 | sc-203315 sc-203315A sc-203315B | 10 mg 25 mg 100 mg | $129.00 $284.00 $1004.00 | 3 | |
Zebularine is a cytidine analog that gets incorporated into DNA and inhibits DNA methylation, which could decrease LGALS9C expression. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram can modulate DNA methylation and histone modification, potentially influencing LGALS9C gene expression. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide may inhibit NF-kB pathway, which can be involved in the transcriptional regulation of various genes, potentially including LGALS9C. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin has multiple cellular targets and has been shown to modulate gene expression, potentially affecting LGALS9C. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG can alter DNA methylation and histone modifications, potentially impacting gene expression. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol influences several signaling pathways and may modulate gene expression, potentially affecting LGALS9C. | ||||||